Certified Global Research Member
Key Questions Answered
- Global Market Outlook
- In-depth analysis of global and regional trends
- Analyze and identify the major players in the market, their market share, key developments, etc.
- To understand the capability of the major players based on products offered, financials, and strategies.
- Identify disrupting products, companies, and trends.
- To identify opportunities in the market.
- Analyze the key challenges in the market.
- Analyze the regional penetration of players, products, and services in the market.
- Comparison of major players’ financial performance.
- Evaluate strategies adopted by major players.
- Recommendations
Why Choose Market Research Future?
- Vigorous research methodologies for specific market.
- Knowledge partners across the globe
- Large network of partner consultants.
- Ever-increasing/ Escalating data base with quarterly monitoring of various markets
- Trusted by fortune 500 companies/startups/ universities/organizations
- Large database of 5000+ markets reports.
- Effective and prompt pre- and post-sales support.
The Cancer Biological Therapy market has experienced a lot of patterns shaping the cancer treatment world. Biological therapies, also known as immunotherapies, have developed into an encouraging avenue for cancer patients thereby revolutionizing conventional methods used to treat the disease. One interesting trend is personalized medicine that focuses more on patient-specific genetic profiles during treatment. Here we leave one-size-fits-all approach and allows more successful and directed interventions.
Moreover, the rise of combination therapies is another key trend in the Cancer Biological Therapy market. The increasing focus on combinations of different biological therapies or mixing up biologic agents with traditional treatments like chemotherapy is being studied by researchers and pharmaceutical companies with a view to exploiting synergistic effects. The aim is to maximize therapy efficacy while minimizing harmful side effects. Combinations of immune checkpoint inhibitors, CAR-T cell therapy, targeted therapies are becoming popular giving hope for tough forms of tumors.
Adoption of next-generation sequencing (NGS) technologies affects market trends too. It provides an opportunity for comprehensive analysis of genetic aberrations within malignant cells thus enabling identification of specific targets for biological therapies. As such, it has resulted in development of more accurate and efficient treatment options leading to better outcomes among patients. On top of that, incorporation of NGS into regular clinical practice continues to increase thereby enhancing progress in cancer biological therapy.
Furthermore, there has been an increase in research and development activities within the Cancer Biological Therapy market. Advanced understanding about cancer biology has led to discovery new therapeutic targets that are underpinning novel biological remedies being introduced into the market place. Exploring novel immune checkpoints, biomarkers as well as therapeutic agents broadens our armamentarium against different cancers types globally This highly dynamic research environment promotes collaborations between academia-industry-regulatory bodies which hastens scientific discoveries’ translation into clinical applications.
Immunotherapy is emerging as a major component within biological therapy segment. Notably, some immune checkpoint inhibitors like PD-1 and PD-L1 inhibitors have shown impressive success in certain cancers bringing about durable responses and long-term survival benefits for patients. Consequently, new immunotherapeutic agents are being approved and integrated into standard treatment protocols thereby changing the cancer treatment landscape across various types of cancer.
Another market trend is the increasing emphasis on biosimilars development in Cancer Biological Therapy segment. These biological products that are highly similar to authorized biologics, referred to as biosimilars, represent a cheaper alternative increasing access to advanced therapies. This movement is especially important in areas where cost considerations dominate health care decisions enabling wider patient reach of efficient anti-cancer treatments.”
APAC Cancer Biological Therapy Market Highlights:
Market Scenario
The Asia Pacific Cancer Biological Therapy Market is expected to reach USD 172,450.2 Million by 2030 at 7.7% CAGR during the forecast period 2022-2030. Cancer is the leading and the second largest cause of death across the globe. The disease is characterized by disordered and deregulated cellular and stromal explosion along with reduced cell death and growth factor deprivation, and others. Biological therapy treatment is done with the help of living organisms, parts of living organisms or laboratory manufactured version of such content. Various types of biological therapies, which inhibit specific molecules involved in development and growth of cancer tumor, such therapies known as; cancer targeted therapies.
The major driving factors for Asia Pacific cancer biological therapy market are increasing cancer survival rates, growing demand for advanced therapies such as biological therapy, growth of cancer healthcare facilities in emerging countries, etc. Additionally, less number of side effects associated with biological therapy as compared to conventional treatment methods is the critical growth factor. Conventional cancer treatment methods like chemotherapy, radiotherapy give effective result, but along with that these methods also show its counter effects on body. The side effects may include, loss of hair, weakened immune system, and such others depending upon the type, and phase of cancer. Biological therapies help to reduce the level of side effects as compared to other treatment methods. Biological therapies are giving the same amount of success rate for curing the cancer patient with 1st stage cancer approximately 27% to 35%. Owing to low level of side effects and high success rate of this therapy, the market is expected to grow rapidly. However, high cost of the treatment may restrain the market growth.
Figure 1: Asia Pacific cancer biological therapy market, by types
Sources: Annual reports, Press release, White paper, Company Presentation
Key Players The leading market players in the Asia Pacific cancer biological therapy market include Merck & Co., Inc. (US), F. Hoffmann-La Roche Ltd (Switzerland), Novartis AG (Switzerland), Amgen Inc. (US), Bristol-Myers Squibb (US), Celgene (US), Eli Lilly and Company (US), EnGeneIC (Australia), Pfizer (US), Intas Pharmaceuticals Ltd. (India), and Sun Pharmaceutical Industries Ltd. (India)
Segmentation Asia Pacific cancer biological therapy market is segmented into types, phases, and end users.
On the basis of types the market is segmented into monoclonal antibodies, interferon, interleukins, cancer growth inhibitors, gene therapy, colony-stimulating factors, targeted therapy, cancer vaccines, and others. On the basis of phases, the market is segmented into phase I, phase II, and phase III.
On the basis of end users, the market is segmented into hospitals & clinics, cancer research centers, laboratories, and others.
Market Assessment 
Sources: Annual reports, World Health Organization (WHO), White paper, Company Presentationa
Regional Analysis China dominates the Asia Pacific cancer biological therapy market owing to increasing prevalence of cancer. Increasing adoption of smoking by people, rapid research & development and presence rapidly developing economy in this region fuel the growth of the market in Asia Pacific. Japan and Australia are other major contributor to the market growth in this region.
Intended Audience
- Pharmaceutical Companies
- Pharmaceutical Suppliers
- Cancer Research Organizations
- Potential Investors
- Key Executive (CEO and COO) and Strategy Growth Manager
- Research Companies
Leading companies partner with us for data-driven Insights
Kindly complete the form below to receive a free sample of this Report
Tailored for You
- Dedicated Research on any specifics segment or region.
- Focused Research on specific players in the market.
- Custom Report based only on your requirements.
- Flexibility to add or subtract any chapter in the study.
- Historic data from 2014 and forecasts outlook till 2040.
- Flexibility of providing data/insights in formats (PDF, PPT, Excel).
- Provide cross segmentation in applicable scenario/markets.
